Clinical trial of hydroxychloroquine in COVID-19 patients paused: WHO

Reuters

25 May 2020 0 shares 1 views

Clinical trial of hydroxychloroquine in COVID-19 patients paused: WHO

Reuters

Published 25 May 2020

A clinical trial of malaria drug hydroxychloroquine in COVID-19 patients has been suspended amid safety concerns, World Health Organization (WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

Full Article

COVID-19 vaccine could be ready by October, claims Global pharmaceutical major Pfizer

Mid-Day 31 May 2020

Global pharmaceutical major Pfizer believes that a vaccine to prevent Covid-19 could be ready by the end of October, the company's..

As Hospitals Walk Tightrope Of Patient Data-Sharing, One System Offers A New Balance
Eurasia Review 31 May 2020
Sanofi Stops Supplying Hydroxychloroquine to COVID-19 Patients in Clinical Trials
Motley Fool 30 May 2020
NA Proactive news snapshot: Helix Technologies, Information Services, Medgold Resources, EXMceuticals UPDATE …
Proactive Investors 29 May 2020
Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials
Reuters India 29 May 2020

More coverage

Scientists raise concern over hydroxychloroquine study

WorldNews 29 May 2020

Dozens of scientists have raised concerns over a large-scale study of hydroxychloroquine and chloroquine that led to the World..

Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns
Reuters India 29 May 2020
NA Proactive news snapshot: Biocept, EnWave, Lingo Media, Maverix Metals UPDATE …
Proactive Investors 29 May 2020
EU regulator wants more data on malaria drug's use for COVID-19
Reuters India 29 May 2020
NA Proactive news snapshot: Thunderbird Entertainment, Codebase Ventures, Phunware, TRACON Pharmaceuticals …
Proactive Investors 29 May 2020

Clinical trial of hydroxychloroquine in COVID-19 patients paused: WHO

Clinical trial of hydroxychloroquine in COVID-19 patients paused: WHO

You might like

Related news coverage

COVID-19 vaccine could be ready by October, claims Global pharmaceutical major Pfizer

Advertisement

More coverage

Scientists raise concern over hydroxychloroquine study